Cladribine in the treatment of multiple sclerosis

نویسنده

  • Per Soelberg Sorensen
چکیده

ISSN 2041-6792 10.4155/CLI.10.32 © 2011 Future Science Ltd Treatment with cladribine leads to a preferential and sustained reduction in lymphocytes and monocytes, resulting in long-lasting depletion of CD4+ and CD8+ T cells. In the Phase III placebo-controlled trial in relapsing–remitting multiple sclerosis (the CLARITY study), oral cladribine at 96 weeks significantly reduced annual relapse rates by 54–57% compared with placebo. The risk of disability progression and brain lesion counts on MRI were also decreased. The therapy was well tolerated. The dosing regimen is convenient, but careful surveillance is still needed to detect unforeseen side effects. Until long-term safety data are available, the use of oral cladribine would primarily be as an escalating therapy in patients with breakthrough disease on IFN-b and glatiramer acetate.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine

Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compo...

متن کامل

Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine

Multiple Sclerosis (MS) is a chronic inflammatory, immune-mediated, demyelinating disorder of the central nervous system with a heterogeneous clinical presentation and pathology in which activated lymphocytes play an important role in mediating tissue damage. Until recently, all first line therapies for MS were injectable. Several oral medications have been studied for preventative treatment of...

متن کامل

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis

Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) products, including IFN β-1a administered intramuscularly or subcutaneously and IFN β-1b subcutaneously, glatiramer acetate, natalizumab, and mitoxantrone are approved disease-modifying therapies for the treatment of relapsing...

متن کامل

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets

BACKGROUND Neuroimaging studies have used magnetic resonance imaging-derived methods to assess brain volume loss in multiple sclerosis (MS) as a reliable measure of diffuse tissue damage. METHODS In the CLARITY study ( ClinicalTrials.gov NCT00213135), the effect of 2 years' treatment with cladribine tablets on annualized percentage brain volume change (PBVC/y) was evaluated in patients with r...

متن کامل

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine

OBJECTIVE To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS). METHODS Meta-analysis of phase III trials of licensed DMDs for pwRMS and a phase III trial of cladribine (CLARITY). Cancer rates were compared using Fisher exact test. RESULTS Eleven trials were included. Investigated treatments included ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2011